This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race Receives Human Ethics Approval for Extramedullary AML & MDS Trial
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has received
human ethics approval for its open label clinical trial of Zantrene® (bisantrene
dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS).
Before patients can be enrolled and treated at the lead site – Calvary Mater Newcastle
Hospital – Race must receive Research Governance Office (RGO) (site budget and
contracting) approval. All required documentation has now been submitted to enable this
outcome. Governance approval is typically received within 4 to 8 weeks from submission.
This open label Phase 1 trial with a dose expansion Phase 2 stage will recruit up to 60
patients with extramedullary AML or MDS using a two-stratum (arm) design (ASX
Announcement: November 1, 2021).